Overview:
Management of breast cancer is rapidly evolving as novel and emerging biomarkers and molecular testing strategies are informing treatment for a more tailored and targeted approach to care. The clinical relevance and appropriate clinical application of emerging biomarkers, including the role of ctDNA, in the management of breast cancer from early stage to advanced disease should be carefully considered in the context of patient-specific characteristics.
This webcast will update clinicians on the role of ctDNA in
the management of breast cancer and will review the latest evidence by examining
the clinical utility of ctDNA in informing breast cancer treatment approaches.
Following didactic presentations on the current and emerging role of ctDNA in
breast cancer management from early to advanced disease, expert faculty will
discuss the latest data on ctDNA and address current clinical challenges, providing
insights into best practices and forward-looking perspectives on biomarker
testing to guide treatment for patients with breast cancer.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Describe the utility of genomic and molecular biomarker assays in supporting individualized treatment selection in early-stage and metastatic breast cancer settings.
- Evaluate efficacy and safety data from pivotal clinical trials to optimize treatment plans for patients with early-stage and advanced/metastatic breast cancer.
David Page, MD
Medical Oncologist
Providence Health & Services
Portland, OR
Pedram Razavi, MD, PhD
Assistant Attending, Department of Medicine
Director, Breast Translational Program and Breast Molecular Tumor
Board
Director, Liquid Biopsy and Cancer Genomics
MSK Global Biomarker Development Program
Memorial Sloan Kettering Cancer Center
New York, NY
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.